NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 ...

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent

Related Keywords

University Of Chicago ,Illinois ,United States ,Texas ,Chapel Hill ,North Carolina ,Florida ,Cambridge ,Cambridgeshire ,United Kingdom ,New York ,Paris ,France General ,France ,Tampa ,University Of North Carolina ,Maryland ,Arizona ,Massachusetts ,Baltimore ,Chicago ,American ,Kedar Kirtane ,Jessica Frakes ,Shetal Patel ,Siddharth Sheth ,David Rolando ,Aditya Joolori ,Trevor Hackman ,Omari Vivar ,Paul Chang ,Jiaxin Niu ,Septimiu Murgu ,Colette Shen ,George Yang ,Tanguy Seiwert ,Jared Weiss ,Jimmy Caudell ,University Of Texas Md Anderson Cancer Center ,Linkedin ,Moffitt Cancer Center ,Twitter ,Given The Company ,Drug Administration ,Nasdaq ,University Of North Carolina School Medicine ,Banner Md Anderson Cancer Center ,Euronext ,Coordinating Investigator Colette Shen ,American Society ,Investigator Colette Shen ,Pavel Tyan ,Zhen Gooi ,Sari Rosenberg ,Laurent Levy ,Sunday June ,North Carolina School ,Cancer Center ,Hopkins Medicine ,United States Food ,Fast Track ,Janssen Pharmaceutica ,Euronext Paris ,Nasdaq Global Select Market ,New York City ,